What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) antagonist for preventing or reducing the severity of an allergic reaction to an allergen in a subject, wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL- 4R, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8, and wherein the IL- 4R antagonist is to be administered to the subject prior to exposure to the allergen.

2. The use of claim 1, wherein the IL-4R antagonist is formulated to be administered to the subject in multiple doses prior to exposure to the allergen.

3. The use of claim 1 or 2, wherein the IL-4R antagonist is formulated to be administered to the subject two weeks prior to exposure to the allergen.

4. The use of any one of claims 1 to 3, wherein the IL-4R antagonist comprises a heavy chain variable region (HCVR) that has the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) that has the amino acid sequence of SEQ ID NO: 2.

5. The use of claim 4, wherein the IL-4R antagonist is dupilumab.

6. The use of any one of claims 1 to 5, wherein the allergic reaction comprises at least one of urticaria, angioedema, rhinitis, allergic asthma, vomiting, respiratory compromise, swollen lips, swollen tongue, and reduced blood pressure.

7. The use of any one of claims 1 to 5, wherein the allergic reaction is anaphylaxis.

8. The use of any one of claims 1 to 7, wherein the allergen is a food item.

9. The use of claim 8, wherein the food item is a dairy product, egg, wheat, soy, fish, shellfish, peanut, or tree nut.

10. The use of any one of claims 1 to 7, wherein the allergen is a non-food allergen.

11. The use of claim 10, wherein the non-food allergen is dust, pollen, insect venom, mold, animal fur, animal dander, wool, latex, a metal, a household cleaner, a detergent, a drug, a therapeutic monoclonal antibody, ragweed, grass, or birch.

12. The use of any one of claims 1 to 11, wherein the IL-4R antagonist is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing.

13. The use of any one of claims 1 to 12, wherein the IL-4R antagonist is for use in combination with a second agent, and wherein the second agent is a steroid, antihistamine, decongestant, or anti-IgE agent.

14. The use of any one of claims 1 to 13, wherein the IL-4R antagonist is formulated to be administered subcutaneously.

15. The use of any one of claims 1 to 14, wherein the IL-4R antagonist is contained in a syringe.

16. The use of any one of claims 1 to 14, wherein the IL-4R antagonist is contained in a pen delivery device.

17. The use of claim 16, wherein the pen delivery device is a prefilled pen delivery device.

18. Use of an interleukin-4 receptor (IL-4R) antagonist in the preparation of a medicament for preventing or reducing the severity of an allergic reaction to an allergen in a subject, wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4R, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino

acid sequence of SEQ ID NO:8, and wherein the medicament is to be administered to the subject prior to exposure to the allergen.

19. The use of claim 18, wherein the medicament is formulated to be administered to the subject in multiple doses prior to exposure to the allergen.

20. The use of claim 18 or 19, wherein the medicament is formulated to be administered to the subject two weeks prior to exposure to the allergen.

21. The use of any one of claims 18 to 20, wherein the IL-4R antagonist comprises a heavy chain variable region (HCVR) that has the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) that has the amino acid sequence of SEQ ID NO: 2.

22. The use of claim 21, wherein the IL-4R antagonist is dupilumab.

23. The use of any one of claims 18 to 22, wherein the allergic reaction comprises at least one of urticaria, angioedema, rhinitis, allergic asthma, vomiting, respiratory compromise, swollen lips, swollen tongue, and reduced blood pressure.

24. The use of any one of claims 18 to 22, wherein the allergic reaction is anaphylaxis.

25. The use of any one of claims 18 to 24, wherein the allergen is a food item.

26. The use of claim 25, wherein the food item is a dairy product, egg, wheat, soy, fish, shellfish, peanut, or tree nut.

27. The use of any one of claims 18 to 24, wherein the allergen is a non- food allergen.

28. The use of claim 27, wherein the non-food allergen is dust, pollen, insect venom, mold, animal fur, animal dander, wool, latex, a metal, a household cleaner, a detergent, a drug, a therapeutic monoclonal antibody, ragweed, grass, or birch.

29. The use of any one of claims 18 to 28, wherein the medicament is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing.

30. The use of any one of claims 18 to 29, wherein the medicament is for use in combination with a second agent, and wherein the second agent is a steroid, antihistamine, decongestant, or anti-IgE agent.

31. The use of any one of claims 18 to 30, wherein the medicament is formulated to be administered subcutaneously.

32. The use of any one of claims 18 to 31, wherein the medicament is contained in a syringe.

33. The use of any one of claims 18 to 31, wherein the medicament is contained in a pen delivery device.

34. The use of claim 33, wherein the pen delivery device is a prefilled pen delivery device.

35. Use of an interleukin-4 receptor (IL-4R) antagonist for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen, wherein the IL-4R antagonist is to be administered to a subject prior to or concurrent with the SIT regimen, wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4R, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), and wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.

36. The use of claim 35, wherein the IL-4R antagonist comprises a heavy chain variable region (HCVR) that has the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) that has the amino acid sequence of SEQ ID NO: 2.

37. The use of claim 36, wherein the IL-4R antagonist is dupilumab.

38. The use of any one of claims 35 to 37, wherein the SIT regimen comprises an up-dosing phase followed by a maintenance phase.

39. The use of claim 38, wherein the SIT regimen is a rush SIT regimen.

40. The use of claim 38 or 39, wherein the IL-4R antagonist is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing, prior to or during the up-dosing phase of the SIT regimen.

41. The use of claim 38 or 39, wherein the IL-4R antagonist is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing, during the maintenance phase of the SIT regimen.

42. The use of claim 38 or 39, wherein the IL-4R antagonist is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing, throughout the entire course of the SIT regimen.

43. The use of claim 38 or 39, wherein the IL-4R antagonist is formulated to be further administered after the maintenance phase of the SIT regimen as once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing.

44. The use of any one of claims 35 to 43, wherein the SIT regimen comprises use of a food allergen derived from a dairy product, egg, wheat, soy, fish, shellfish, peanut, or tree nut.

45. The use of any one of claims 35 to 43, wherein the SIT regimen comprises use of a non-food allergen selected from the group consisting of dust, pollen, insect venom, mold, animal fur, animal dander, wool, latex, a metal, a household cleaner, a detergent, a drug, a therapeutic monoclonal antibody, ragweed, grass, or birch.

46. The use of any one of claims 35 to 45, wherein the IL-4R antagonist is for use in combination with a second agent, and wherein the second agent is a steroid, antihistamine, decongestant, or anti-IgE agent.

47. The use of any one of claims 35 to 46, wherein the IL-4R antagonist is formulated to be administered subcutaneously.

48. The use of any one of claims 35 to 47, wherein the IL-4R antagonist is contained in a syringe.

49. The use of any one of claims 35 to 47, wherein the IL-4R antagonist is contained in a pen delivery device.

50. The use of claim 49, wherein the pen delivery device is a prefilled pen delivery device.

51. Use of an interleukin-4 receptor (IL-4R) antagonist for preventing or reducing the severity of an allergic reaction in a subject having an allergy to a peanut allergen, wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4R, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8, and wherein the IL- 4R antagonist is to be administered to the subject prior to exposure to the peanut allergen.

52. The use of claim 51, wherein the IL-4R antagonist is formulated to be administered to the subject in multiple doses prior to exposure to the peanut allergen.

53. The use of claim 51 or 52, wherein the allergic reaction comprises at least one of urticaria, angioedema, rhinitis, allergic asthma, vomiting, respiratory compromise, swollen lips, swollen tongue, and reduced blood pressure.

54. The use of claim 51 or 52, wherein the allergic reaction is anaphylaxis.

55. The use of any one of claims 51 to 54, wherein the IL-4R antagonist comprises a heavy chain variable region (HCVR) that has the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) that has the amino acid sequence of SEQ ID NO: 2.

56. The use of claim 55, wherein the IL-4R antagonist is dupilumab.

57. The use of any one of claims 51 to 56, wherein the IL-4R antagonist is formulated for once a week dosing or once every two weeks dosing.

58. The use of any one of claims 51 to 57, wherein the IL-4R antagonist is formulated to be administered subcutaneously.

59. The use of any one of claims 51 to 58, wherein the IL-4R antagonist is contained in a syringe.

60. The use of any one of claims 51 to 58, wherein the IL-4R antagonist is contained in a pen delivery device.

61. The use of claim 60, wherein the pen delivery device is a prefilled pen delivery device.

62. Use of an interleukin-4 receptor (IL-4R) antagonist in the preparation of a medicament for preventing or reducing the severity of an allergic reaction in a subject having an allergy to a peanut allergen, wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4R, wherein the antibody or antigen- binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8, and wherein the medicament is to be administered to the subject prior to exposure to the peanut allergen.

63. The use of claim 62, wherein the medicament is formulated to be administered to the subject in multiple doses prior to exposure to the peanut allergen.

64. The use of claim 62 or 63, wherein the allergic reaction comprises at least one of urticaria, angioedema, rhinitis, allergic asthma, vomiting, respiratory compromise, swollen lips, swollen tongue, and reduced blood pressure.

65. The use of claim 62 or 63, wherein the allergic reaction is anaphylaxis.

66. The use of any one of claims 62 to 65, wherein the IL-4R antagonist comprises a heavy chain variable region (HCVR) that has the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) that has the amino acid sequence of SEQ ID NO: 2.

67. The use of claim 66, wherein the IL-4R antagonist is dupilumab.

68. The use of any one of claims 62 to 67, wherein the medicament is formulated for once a week dosing or once every two weeks dosing.

69. The use of any one of claims 62 to 68, wherein the medicament is formulated to be administered subcutaneously.

70. The use of any one of claims 62 to 69, wherein the medicament is contained in a syringe.

71. The use of any one of claims 62 to 69, wherein the medicament is contained in a pen delivery device.

72. The use of claim 71, wherein the pen delivery device is a prefilled pen delivery device.

73. Use of an interleukin-4 receptor (IL-4R) antagonist for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen, wherein the allergen is a peanut allergen, wherein the IL-4R antagonist is to be administered to a subject prior to or concurrent with the SIT regimen, wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof that binds IL-4R, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), and wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.

74. The use of claim 73, wherein the SIT regimen comprises an up-dosing phase followed by a maintenance phase.

75. The use of claim 74, wherein the SIT regimen is a rush SIT regimen.

76. The use of claim 74 or 75, wherein the IL-4R antagonist is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing, prior to or during the up-dosing phase.

77. The use of claim 74 or 75, wherein the IL-4R antagonist is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing, during the maintenance phase.

78. The use of claim 74 or 75, wherein the IL-4R antagonist is formulated for once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing, throughout the entire course of the SIT regimen.

79. The use of claim 74 or 75, wherein the IL-4R antagonist is formulated to be further administered after the maintenance phase of the SIT regimen as once a week dosing, once every two weeks dosing, once every three weeks dosing, or once a month dosing.

80. The use of any one of claims 73 to 79, wherein the IL-4R antagonist comprises a heavy chain variable region (HCVR) that has the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) that has the amino acid sequence of SEQ ID NO: 2.

81. The use of claim 80, wherein the IL-4R antagonist is dupilumab.

82. The use of any one of claims 73 to 81, wherein the IL-4R antagonist is for use in combination with a second agent, and wherein the second agent is a steroid, antihistamine, decongestant, or anti-IgE agent.

83. The use of any one of claims 73 to 82, wherein the IL-4R antagonist is formulated to be administered subcutaneously.

84. The use of any one of claims 73 to 83, wherein the IL-4R antagonist is contained in a syringe.

85. The use of any one of claims 73 to 83, wherein the IL-4R antagonist is contained in a pen delivery device.

86. The use of claim 85, wherein the pen delivery device is a prefilled pen delivery device.